Outlier Mining in High Throughput Screening Experiments
暂无分享,去创建一个
Rudi Verbeeck | Luc Wouters | Michael F M Engels | Greet Vanhoof | R. Verbeeck | G. Vanhoof | L. Wouters | M. Engels
[1] Desire L. Massart,et al. Robust orthogonal regression for the outlier detection when comparing two series of measurement results , 1997 .
[2] Malcolm J. McGregor,et al. Pharmacophore Fingerprinting. 1. Application to QSAR and Focused Library Design , 1999, J. Chem. Inf. Comput. Sci..
[3] T R Ward,et al. Empirical modeling of an in vitro activity of polychlorinated biphenyl congeners and mixtures. , 1997, Environmental health perspectives.
[4] Toshio Fujita,et al. Quantitative structure-activity studies of pyrethroids: 14. Physicochemical structural effects of tetramethrin and its related compounds on knockdown activity against house flies , 1988 .
[5] S. J. Press,et al. Choosing between Logistic Regression and Discriminant Analysis , 1978 .
[6] P. McCullagh,et al. Generalized Linear Models , 1992 .
[7] Vic Barnett,et al. Outliers in Statistical Data , 1980 .
[8] D. M. Hawkins. Multivariate outlier detection , 1980 .
[9] David Harding,et al. Development of an automated high-throughput screening system : a case history , 1997 .
[10] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .
[11] Rudi Verbeeck,et al. CerBeruS: A System Supporting the Sequential Screening Process , 2000, J. Chem. Inf. Comput. Sci..
[12] Mary Jo Wildey,et al. Allegro™: Moving the Bar Upwards , 1999 .
[13] J J Burbaum,et al. The Evolution of Miniaturized Well Plates , 2000, Journal of biomolecular screening.
[14] J H Zhang,et al. Confirmation of primary active substances from high throughput screening of chemical and biological populations: a statistical approach and practical considerations. , 2000, Journal of combinatorial chemistry.
[15] G. V. Kass,et al. Location of Several Outliers in Multiple-Regression Data Using Elemental Sets , 1984 .
[16] Ajay,et al. Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? , 1998, Journal of medicinal chemistry.
[17] A. Atkinson. Fast Very Robust Methods for the Detection of Multiple Outliers , 1994 .
[18] Alan Dove,et al. Drug screening—beyond the bottleneck , 1999, Nature Biotechnology.
[19] J. Mason,et al. New 4-point pharmacophore method for molecular similarity and diversity applications: overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures. , 1999, Journal of medicinal chemistry.
[20] Jiawei Han,et al. Data Mining: Concepts and Techniques , 2000 .
[21] Wilhelm Stahl,et al. What is the Future of High Throughput Screening? , 1999, Journal of biomolecular screening.
[22] Yvonne C. Martin,et al. The Information Content of 2D and 3D Structural Descriptors Relevant to Ligand-Receptor Binding , 1997, J. Chem. Inf. Comput. Sci..
[23] Yvonne C. Martin,et al. Use of Structure-Activity Data To Compare Structure-Based Clustering Methods and Descriptors for Use in Compound Selection , 1996, J. Chem. Inf. Comput. Sci..
[24] Thomas D. Y. Chung,et al. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.
[25] Robin W. Spencer. Diversity Analysis in High Throughput Screening , 1997 .
[26] Paul Labute,et al. Binary Quantitative Structure-Activity Relationship (QSAR) Analysis of Estrogen Receptor Ligands , 1999, J. Chem. Inf. Comput. Sci..
[27] Toshio Fujita,et al. Quantitative structure-Activity studies of pyrethroids: 28. Type differentiation of action-potential changes in crayfish giant axons caused by substituted benzyl chrysanthemates and pyrethrates , 1991 .
[28] M. Boyd,et al. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. , 1989, Journal of the National Cancer Institute.
[29] H. Kubinyi,et al. A scoring scheme for discriminating between drugs and nondrugs. , 1998, Journal of medicinal chemistry.
[30] Philip M. Dean,et al. Molecular diversity in drug design , 2002 .